- Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia
- Author:American College of Obstetricians and Gynecologists (ACOG)
- Published:September 1, 2023
- Outpatient Treatment of Confirmed COVID-19
- Author:American College of Physicians (ACP)
- Published:September 19, 2023
- Optimal Timing of Elective Hip or Knee Arthroplasty for Patients with Symptomatic Moderate to Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis with Secondary Arthritis for Whom Nonoperative Therapy is Ineffective
- Author:American College of Rheumatology (ACG); American Association of Hip and Knee Surgeons (AAHKS)
- Published:September 25, 2023
- Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Author:American Society of Clinical Oncology (ASCO)
- Published:September 29, 2023
- Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
- Author:American Thoracic Society (ATS)
- Published:September 29, 2023
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH)
- Society:American Urological Association (AUA)
- Published:September 14, 2023
- Diagnosis and Treatment of Early-Stage Testicular Cancer
- Society:American Urological Association (AUA)
- Published:September 14, 2023
- Patients With Chiari Malformation: Diagnosis
- Society:Congress of Neurological Surgeons (CNS)
- Published:September 1, 2023
- Patients With Chiari Malformation: Symptoms
- Society:Congress of Neurological Surgeons (CNS)
- Published:September 1, 2023
- Patients With Chiari Malformation: Surgical Interventions
- Society:Congress of Neurological Surgeons (CNS)
- Published:September 1, 2023
- Pharmacotherapy in Patients With Stable COPD
- Society:Canadian Thoracic Society (CTS)
- Published:September 8, 2023
- Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
- Society:United States Department of Health and Human Services (DHHS)
- Published:September 25, 2023
- Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV
- Society:United States Department of Health and Human Services (DHHS)
- Published:September 14, 2023
- COVID-19 Guideline Part 3: Molecular Testing
- Society:Infectious Diseases Society of America (IDSA)
- Published:September 6, 2023
- Rapid Sequence Intubation in the Critically Ill Adult Patient
- Society:Society of Critical Care Medicine (SCCM)
- Published:September 14, 2023
- Immunotherapy for the Treatment of Hepatocellular Carcinoma
- Society:Society for Immunotherapy of Cancer (SITC)
- Published:September 7, 2023
- Hypertensive Disorders of Pregnancy: Screening
- Society:U.S. Preventive Services Task Force (USPSTF)
- Published:September 2023
- Aphexda (BioLineRx)
- In combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
- Temodar (Merck) Expanded Indication
- Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma; treatment of adults with refractory anaplastic astrocytoma.
- Ojjaara (GlaxoSmithKline)
- Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
- Talicia (RedHill Biopharma) New Formulation
- New simplified dosing regimen – three times daily (TID) regimen for H. pylori eradication.
- Jardiance (Boehringer Ingelheim / Eli Lilly) New Indication
- To reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
- Exxua (Fabre-Kramer Pharmaceutical)
- To treat major depressive disorder.
- Likmez (Saptalis Pharmaceuticals / Appili Therapeutics)
- Treatment of Parasitic and Anaerobic Bacterial Infections.
- Ryzumvi (Viatris / Ocuphire Pharma)
- Treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
- Bosulif (Pfizer)
- For pediatric patients aged 1 year or older with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) that is either newly diagnosed or resistant/intolerant to prior therapy.
- Entyvio (Takeda) New Formulation
- Subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) following induction therapy with intravenous administration of vedolizumab.
- Pombiliti + Opfolda (Amicus Therapeutics)
- To treat late-onset Pompe disease.
Copyright © 2023 Guideline Central, All rights reserved.